Aspire BioPharma is trading at $9.18, up 10.34% during the September 28 session, with the catalyst unclear.
- No company-specific announcement explaining the gain was identified; the latest surfaced company news was a September 9 share repurchase announcement, which predates the session.
- Broader markets were lower amid U.S.–Iran tensions, rising oil prices, and higher Treasury yields; that backdrop does not explain the stock’s rise.